Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study. - Wikidata - awgldk - TriplyDB

Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.

Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.

http://www.wikidata.org/entity/Q37425848

about

Second-line treatment of metastatic gastric cancer: Current options and future directions Targeted therapy for esophagogastric cancers: a review Second-line chemotherapy for advanced gastric cancer in Korea.

P2860

Q26778027-89AD6F08-5AD9-4D83-81C8-B220CC466748 Q36039645-FC5270A0-F11C-4662-B480-B245FD5F2F9B Q37992841-17C24DBB-0023-4649-8025-50B5C54F3D2B

P2860

Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.

http://www.wikidata.org/entity/Q37425848

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2005

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Biweekly irinotecan and cispla ...... a multicenter phase II study.

@en

Biweekly irinotecan and cispla ...... a multicenter phase II study.

@nl

type

label

Biweekly irinotecan and cispla ...... a multicenter phase II study.

@en

Biweekly irinotecan and cispla ...... a multicenter phase II study.

@nl

prefLabel

Biweekly irinotecan and cispla ...... a multicenter phase II study.

@en

Biweekly irinotecan and cispla ...... a multicenter phase II study.

@nl

P1433

Q37425848-45EDC66C-46D8-42D2-9705-CFACCB2166B8

P1476

Q37425848-590A1C75-5BA7-4326-8F6E-859BA32ACE7B

P2093

Q37425848-03A95A0D-1A5B-46DC-B233-5DA629C0A093

Q37425848-101B76E6-2E24-415A-ABE9-969B05D78E7F

Q37425848-1029B744-937B-42F2-9199-CB486886080C

Q37425848-290C8E15-BEAC-480C-9D64-D2E46C6C3A91

Q37425848-29AD0295-D877-476A-A9DA-57530389C12C

Q37425848-2A03316F-F680-41E8-B309-DBEF5921BAD2

Q37425848-35DA0DC0-28BE-4CA7-8EC4-35EA8FD69063

Q37425848-5BFC90DF-CBAB-40C0-9C83-8597F375CA4F

Q37425848-89A9FF14-DDEE-4F8B-B2E5-8170DC236CAC

Q37425848-8D4697C0-F32F-467B-AB3F-276EF14C5BE8

P2860

Q37425848-01F58004-33BA-48DF-B84D-BCC58412C8DE

Q37425848-07775C79-83BC-4853-9000-594FA3EB40FF

Q37425848-0AAC0814-A4DC-4644-B41E-E226F56F10E7

Q37425848-142CCDE0-AE6F-47FF-A264-97936DBB19BE

Q37425848-22AE0B2D-FE17-46DE-AD86-410E120AE2F2

Q37425848-33AF6F91-76BF-478A-AD9B-114EB45B59B2

Q37425848-3E3F8518-4B5B-466D-819C-05BBB948E6B6

Q37425848-6AFD1C33-6D8D-4186-9734-B67FCC1FFFE1

Q37425848-7194C9C6-0B02-42EF-A6EC-F9D8CAF38A97

Q37425848-7D296280-3AC5-435F-B04F-09509E95834D

P304

Q37425848-0D7017F1-A055-4482-8CCB-8E41CB273104

P31

Q37425848-10CAD3BE-54CC-434B-AF81-79CACA0E2391

P356

Q37425848-748643D4-149A-4915-9084-BABDB35E5DAF

P433

Q37425848-64605403-51E6-467D-8277-AB46A3319E82

P478

Q37425848-2ECF2DD8-CCAE-4307-A702-E706DBECAC66

P577

Q37425848-80894833-B495-45D0-944F-E30F78190404

P5875

Q37425848-95CF354B-937B-4F21-AF77-B6094A9DD2C6

P698

Q37425848-768808E6-5279-4D0E-9301-9340B7549E4D

P921

Q37425848-9E15D684-79BD-471E-8282-B8622637B736

Q37425848-ABE34F1F-08EA-4400-8755-4E2B24AAE607

P932

Q37425848-E4457FAC-89BA-45B1-86F9-5B0F8F32E9A9

P356

JKMS.2005.20.6.966

P1433

Journal of Korean Medical Science

P1476

Biweekly irinotecan and cispla ...... a multicenter phase II study.

@en

P2093

Dong Hwan Kim

http://www.w3.org/2001/XMLSchema#string

Ho Young Chung

http://www.w3.org/2001/XMLSchema#string

Hong Suk Song

http://www.w3.org/2001/XMLSchema#string

Hun Mo Ryoo

http://www.w3.org/2001/XMLSchema#string

Jin Ho Baek

http://www.w3.org/2001/XMLSchema#string

Jong Gwang Kim

http://www.w3.org/2001/XMLSchema#string

Keon Uk Park

http://www.w3.org/2001/XMLSchema#string

Ki Young Kwon

http://www.w3.org/2001/XMLSchema#string

Kyu Bo Lee

http://www.w3.org/2001/XMLSchema#string

Kyung Hee Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer.

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.

Docetaxel-based chemotherapy in the treatment of gastric cancer.

Current treatments and future perspectives in colorectal and gastric cancer

Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.

P304

966-970

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3346/JKMS.2005.20.6.966

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7408334

http://www.w3.org/2001/XMLSchema#string

P698

16361806

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2779328

http://www.w3.org/2001/XMLSchema#string